Skip to main content
. 2018 Nov 1;8(11):2267–2283.

Figure 3.

Figure 3

Effects of AMR-MeOAc and FL118 alone and in combination on mutant KRASG12D activity and downstream signaling. A. HPAF-II cells were treated with 8 µM AMR-MeOAc or 20 nM FL118 alone and in combination for 6, 12, 24, and 48 h. RAS Pull-Down assays and Western blot analysis using KRAS (G12D) and total Ras antibodies were performed to measure the activated KRAS and total RAS protein expressions. B. HPAF-II cells were treated for 12, 24 and 48 h with 8 µM AMR-MeOAc and 20 nM FL118 either alone or in combination, and analyzed for the expressions of B-RAF, ERK, p-ERK and p-AKT by Western blots. C. Cell cycle distribution after AMR-MeOAc and FL118 treatment alone or in combination. After HPAF-II cells treated with 3 µM AMR-MeOAc and 10 nM FL118 alone or in combination for 48 h, cell cycle distribution was analyzed by flow cytometry. D. The percentage of cells at each phase of cell cycle (G0/G1, S and G2/M) was quantified and represented in histogram. Each bar is the mean ± SD derived from three independent experiments.